<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04243499</url>
  </required_header>
  <id_info>
    <org_study_id>ICT01-101</org_study_id>
    <nct_id>NCT04243499</nct_id>
  </id_info>
  <brief_title>First-in-Human Study of ICT01 in Patients With Advanced Cancer</brief_title>
  <acronym>EVICTION</acronym>
  <official_title>A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImCheck Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImCheck Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as&#xD;
      monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort&#xD;
      examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort&#xD;
      expansion into 2-3 solid tumor indications and one hematologic malignancy for ICT01&#xD;
      monotherapy, and 1-2 solid tumor indication receiving ICT01 plus pembrolizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be assigned to a dose level of ICT01 at the time of their enrollment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (Parts 1 &amp; 2)</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate using RECIST for solid tumor patients (Part 2)</measure>
    <time_frame>6 months</time_frame>
    <description>RECIST is measured every 8 weeks during treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate using RECIL for lymphoma patients (Part 2)</measure>
    <time_frame>6 months</time_frame>
    <description>RECIL is measured every 8 weeks during treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Number of Circulating Gamma Delta T Cells</measure>
    <time_frame>28 days</time_frame>
    <description>Flow cytometric counting of circulating gamma delta T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Activation State of Circulating Gamma Delta T Cells</measure>
    <time_frame>28 days</time_frame>
    <description>Flow cytometric measurement of CD69 and Ki67 expression on gamma delta T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax following the first dose of ICT01</measure>
    <time_frame>1 day</time_frame>
    <description>PK parameter from serum ICT01 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC following the first dose of ICT01</measure>
    <time_frame>21 days</time_frame>
    <description>PK parameter from serum ICT01 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance at steady-state of ICT01</measure>
    <time_frame>6 months</time_frame>
    <description>PK parameter from serum ICT01 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of ICT01</measure>
    <time_frame>6 months</time_frame>
    <description>PK parameter from serum ICT01 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate using iRECIST for solid tumor patients (Part 2)</measure>
    <time_frame>6 months</time_frame>
    <description>iRECIST is measured every 8 weeks during treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Hematopoietic/Lymphoid Cancer</condition>
  <arm_group>
    <arm_group_label>IV ICT01 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to six ICT01 dose levels administered as IV monotherapy every 3 weeks will be tested in Part 1 Dose Escalation and up to 2 dose levels in Part 2 Cohort Expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV ICT01 + IV Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A range of IV ICT01 doses administered every 3 weeks will be tested in combination with 200 mg pembrolizumab in Part 1 Dose Escalation and up to 2 dose levels of ICT01 plus 200 mg pembrolizumab in Part 2 Cohort Expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IV ICT01</intervention_name>
    <description>humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody</description>
    <arm_group_label>IV ICT01 + IV Pembrolizumab</arm_group_label>
    <arm_group_label>IV ICT01 Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily signed informed consent form.&#xD;
&#xD;
          2. Relapsed/refractory patients with histologically or cytologically confirmed diagnosis&#xD;
             of advanced-stage or recurrent cancer, including:&#xD;
&#xD;
             Group A: bladder, breast, colon, gastric, melanoma, ovarian, prostate and PDAC Group&#xD;
             B: hematologic malignancies including acute myeloid leukemia, acute lymphocytic&#xD;
             leukemia, Diffuse large B cell lymphoma and follicular lymphoma Group C: melanoma,&#xD;
             cervical, bladder, gastric, head and neck SCC, and lymphoma (according to the approved&#xD;
             package labeling of the ICI)&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1&#xD;
&#xD;
          4. Life expectancy &gt; 3 months as assessed by the Investigator&#xD;
&#xD;
          5. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST)/ Response Evaluation Criteria in Lymphoma (RECIL) or &gt;5% marrow blasts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any malignancy of Vγ9Vδ2 T cell origin&#xD;
&#xD;
          2. Any anti-tumor-directed drug therapy within 28 days or 5 times the elimination&#xD;
             half-life (whichever is shorter) before study treatment (does not apply to patients&#xD;
             receiving ICI for the combination arm)&#xD;
&#xD;
          3. Treatment with investigational drug(s) within 28 days before study treatment&#xD;
&#xD;
          4. Systemic steroids at a daily dose of &gt; 10 mg of prednisone, &gt; 2 mg of dexamethasone or&#xD;
             equivalent, for the last 28 days and need for ongoing treatment.&#xD;
&#xD;
          5. Patients with rapidly progressing disease defined as advanced/metastatic, symptomatic,&#xD;
             visceral spread, with a risk of life-threatening complications in the short term&#xD;
             (e.g., during Screening Period/ treatment washout) that includes patients with massive&#xD;
             uncontrolled effusions pleural, pericardial, peritoneal, pulmonary lymphangitis, and&#xD;
             over 50% liver involvement&#xD;
&#xD;
          6. Ongoing immune-related adverse events (irAEs) and/or AEs ≥grade 2 not resolved from&#xD;
             previous therapies except vitiligo, stable neuropathy up to grade 2, hair loss, and&#xD;
             stable endocrinopathies with replacement hormone therapy.&#xD;
&#xD;
          7. Within 4 weeks of major surgery&#xD;
&#xD;
          8. Documented history of active autoimmune disorders requiring systemic immunosuppressive&#xD;
             therapy within the last 12 months&#xD;
&#xD;
          9. Primary or secondary immune deficiency&#xD;
&#xD;
         10. Active and uncontrolled infections requiring intravenous antibiotic or antiviral&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Frohna, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ImCheck Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Frohna, MD, PhD</last_name>
    <phone>8582055285</phone>
    <email>paul.frohna@imcheck.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priscilla Steve</last_name>
      <email>priscilla.steve@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia LoRusso, DO,</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Neto</last_name>
      <email>joana.neto@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Christiane Jungels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Karsenty</last_name>
      <email>KARSENTYJ@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert Vey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manare ALI</last_name>
      <email>Manare.ALI@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Aurelien Marabelle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Carl Gustav Carus Clinical Trial Unit</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophia Tischer</last_name>
      <email>Sophia.Tischer@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Martin Wermke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Instiute of Oncology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Farras LLansana</last_name>
      <email>nfarras@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Elena Garralda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Cancer Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Daly</last_name>
      <email>robert.daly@icr.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Johann de Bono, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gamma delta T cells</keyword>
  <keyword>butyrophilin</keyword>
  <keyword>pembrolizumab</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

